Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              SK Biopharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              KOREA, REPUBLIC OF Korea, Republic Of

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              The Boulder Peptide Society

              Participation Not Confirmed

              Update your events

              SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia

              Contact the Supplier

              Lead Product(s): Cenobamate

              Therapeutic Area: Neurology Product Name: Xcopri

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 10, 2020

              Details:

              The Phase 3 trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of cenobamate as an adjunctive therapy in subjects with partial-onset seizures, with an optional open-label extension.

              SK Biopharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              KOREA, REPUBLIC OF Korea, Republic Of

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              The Boulder Peptide Society

              Participation Not Confirmed

              Update your events

              SK Biopharmaceuticals Set to Make Historic IPO

              Contact the Supplier

              Lead Product(s): Cenobamate

              Therapeutic Area: Neurology Product Name: Xcopri

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $800.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering June 19, 2020

              Details:

              SK Biopharmaceuticals Co Ltd priced its initial public offering on Friday at the top of its indicative range, aiming to raise 959 billion won ($794 million) in South Korea's biggest IPO in three years.

              SK Biopharmaceuticals

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              KOREA, REPUBLIC OF Korea, Republic Of

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              The Boulder Peptide Society

              Participation Not Confirmed

              Update your events

              SK Biopharmaceuticals Emerges from Pandemic Delays with Pitch for $822M IPO

              Contact the Supplier

              Lead Product(s): Cenobamate

              Therapeutic Area: Neurology Product Name: Xcopri

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $822.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering June 15, 2020

              Details:

              Proceeds will be used accelerate further advancement of the Company's pipeline which include, cenobamate, solriamfetol and among others.

              PharmaCompass__DigitalAd